title: 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning.
abstract: Acutely administered 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') has been proposed to have long-term positive effects on post-traumatic stress disorder (PTSD) symptoms when combined with psychotherapy. No preclinical data support a mechanistic basis for these claims. Given the persistent nature of psychotherapeutic gains facilitated by MDMA, we hypothesized that MDMA improves fear extinction learning, a key process in exposure-based therapies for PTSD. In these experiments, mice were first exposed to cued fear conditioning and treated with drug vehicle or MDMA before extinction training 2 days later. MDMA was administered systemically and also directly targeted to brain structures known to contribute to extinction. In addition to behavioral measures of extinction, changes in mRNA levels of brain-derived neurotrophic factor (Bdnf) and Fos were measured after MDMA treatment and extinction. MDMA (7.8 mg kg(-1)) persistently and robustly enhanced long-term extinction when administered before extinction training. MDMA increased the expression of Fos in the amygdala and medial prefrontal cortex (mPFC), whereas increases in Bdnf expression were observed only in the amygdala after extinction training. Extinction enhancements were recapitulated when MDMA (1 μg) was infused directly into the basolateral complex of the amygdala (BLA), and enhancement was abolished when BDNF signaling was inhibited before extinction. These findings suggest that MDMA enhances fear memory extinction through a BDNF-dependent mechanism, and that MDMA may be a useful adjunct to exposure-based therapies for PTSD and other anxiety disorders characterized by altered fear learning.
authors.affiliation: Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
authors.forename: M B
authors.initials: MB
authors.lastname: Young
authors.affiliation: Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.|Department of Psychiatry and Behavioral Science, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
authors.forename: R
authors.initials: R
authors.lastname: Andero
authors.affiliation: Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.|Department of Psychiatry and Behavioral Science, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.|Howard Hughes Medical Institute, Chevy Chase, MD, USA.
authors.forename: K J
authors.initials: KJ
authors.lastname: Ressler
authors.affiliation: Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.|Department of Psychiatry and Behavioral Science, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
authors.forename: L L
authors.initials: LL
authors.lastname: Howell
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects*; D005108:Extinction, Psychological / Q000187:drug effects*; D005239:Fear / Q000187:drug effects*; D006213:Hallucinogens / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D023421:Models, Animal; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology*
chemical_list: D006213:Hallucinogens; D018817:N-Methyl-3,4-methylenedioxyamphetamine